Europe Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As Europe rethinks the balance between affordability, resilience and innovation, Michal Nitka, SVP, Head Generics Europe & Global Head OTC at…
Europe Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this squeeze but thriving in it – through diversification, geographic focus, R&D intensity, or sheer scientific specialisation. Here’s how four of…
USA Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US leadership, expanding pipeline, vertical integration, and focus on patient access. Salsi goes on to stresses that long-term biosimilar growth depends…
USA Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs Punit Patel, President and CEO, of Zydus Americas, speaks about leading the company’s pivot from a pure-play generics business into complex generics, biosimilars and new chemical entities. Anchored by its…
Germany We have set out a clear strategy, but strategy only provides direction; ultimately, trust is built through execution Europe pioneered the biosimilars industry and remains its most advanced market, yet sustaining that leadership is becoming increasingly challenging as pricing pressures, manufacturing economics and global competition reshape the sector. As Formycon…
USA Dr Maisha Draves, Associate Executive Director of The Permanente Medical Group (TPMG), speaks to the group’s approach to integrating the use of biosimilars across the care network. By focusing on rigorous research evaluation and peer-to-peer education, TPMG has become a national frontrunner in the uptake of formulary inclusion and the…
USA Tom Shea, Founder and CEO of Meitheal Pharmaceuticals, discusses his career across commercial and operational roles in generic injectables and the creation of Meitheal in 2017. He highlights the company’s growth into a top-five US injectable generic player, its expansion into biosimilars, and its commitment to manufacturing investment, supply reliability,…
USA If price is the only basis for adoption, biosimilars will not survive as a viable industry Tom Newcomer, SVP & Head of US Commercial, Samsung Bioepis, discusses the company’s evolution into a dedicated biosimilars developer with ten FDA approvals and a long-term commitment to improving affordability and access. He highlights…
USA A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for Accessible Medicines. Following leadership changes within the FDA, actively prioritizing generic and biosimilar medicines must remain a top focus…
USA Harshika Sarbajna, SVP Commercial Global at Alvotech, reflects on the evolution of the US biosimilars market and the company’s strategy for scaling access across key therapeutic areas. In this interview, she discusses launch execution, payer dynamics, interchangeability, and the role of partnerships in driving adoption. She also outlines how pricing…
Europe Against a backdrop of rising geopolitical tension, regulatory fragmentation, and mounting pressure on Europe’s healthcare systems, Prague-headquartered Zentiva is positioning itself as a distinctly European pharmaceutical player focused on long-term resilience, affordability, and supply security. CEO Steffen Saltofte reflects on the company’s transformation since its carve out from Sanofi, its…
USA Chrys Kokino, President of Accord North America, discusses the strategic evolution of the US biosimilar market and Accord’s mission to move beyond single-asset competition toward a comprehensive treatment portfolio. Drawing on his experience as a global pioneer at Sandoz and Mylan, Kokino details how he and his team have been…
See our Cookie Privacy Policy Here
